Evotec has completed its deal to acquire Just Biotherapeutics, accelerating Evotec’s long-term strategy to strengthen its multimodality approach to R&D, and expanding its U.S. footprint and machine learning capabilities. Evotec acquired Just.Bio to integrate their machine-learning technologies and flexible methods for the design, development, and manufacture of biologics into Evotec’s drug discovery offerings. Just.Bio’s approximately 95 employees and its biologic developm...